Business Description
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
Business History
Price Overview
Last updated: Jun 27, 2026 9:01am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 3.75
Total Equity: $49.46B
Shares: 1,288,100,000
Total Debt: $27.96B
Cash: $1.95B
EBITDA: $9.81B
Total Debt: $27.96B
Cash: $1.95B
Revenue: $36.36B
Revenue: $36.36B
Revenue: $36.36B
Total Equity: $49.46B
Tax Rate: 21.2%
Equity: $49.46B
Total Debt: $27.96B
Cash: $1.95B
Current Liabilities: $11.66B
Long-Term Debt: $26.17B
Total Debt: $27.96B
Total Equity: $49.46B
Shares: 1,288,100,000
Shares: 1,288,100,000
CapEx: -$1.90B
Shares: 1,288,100,000
Stock Price: $80.98
Net Income: $4.80B
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 23, 2026 3:02am (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | $31.7B | $31.2B | $32.4B | $33.5B | $36.4B |
| Cost of Revenue | $10.1B | $10.7B | $11.2B | $11.6B | $12.7B |
| Gross Profit | $21.5B | $20.5B | $21.1B | $21.9B | $23.6B |
| Operating Expenses | $15.8B | $15.0B | $16.0B | $16.0B | $17.2B |
| Operating Income | $5.8B | $5.5B | $5.1B | $6.0B | $6.5B |
| Net Income | $5.0B | $3.8B | $3.7B | $4.7B | $4.8B |
| EBITDA | $8.8B | $8.7B | $8.2B | $9.2B | $9.8B |
| EPS | $3.75 | $2.83 | $2.77 | $3.63 | $3.75 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 23, 2026 3:02am (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $3.7B | $1.5B | $1.3B | $2.2B | $1.9B |
| Total Current Assets | $23.1B | $21.7B | $21.9B | $23.8B | $24.8B |
| Total Assets | $91.0B | $90.9B | $90.0B | $91.7B | $93.0B |
| Current Liabilities | $12.4B | $9.1B | $10.8B | $12.9B | $11.7B |
| Long-Term Debt | $20.3B | $24.3B | $23.9B | $25.6B | $26.2B |
| Total Liabilities | $38.3B | $39.3B | $39.6B | $43.4B | $43.0B |
| Total Equity | $52.6B | $51.5B | $50.2B | $48.0B | $49.5B |
| Retained Earnings | $30.3B | $30.4B | $30.4B | $31.5B | $32.6B |
Cash Flow (Annual)
Last updated: Jun 23, 2026 3:02am (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $7.3B | $6.0B | $6.8B | $7.0B | $7.3B |
| Capital Expenditure | -$1.4B | -$1.5B | -$1.6B | -$1.9B | -$1.9B |
| Free Cash Flow | $6.0B | $4.6B | $5.2B | $5.2B | $5.4B |
| Acquisitions (net) | -$91.0M | -$1.9B | -$211.0M | -$98.0M | -$406.0M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$2.5B | -$645.0M | -$2.1B | -$3.2B | -$1.0B |
| Net Change in Cash | $121.0M | -$2.2B | -$259.0M | $934.0M | -$269.0M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 9:01am (just now)| Metric | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|
| Revenue |
$40.0B $37.3B – $41.0B
|
$41.7B $41.6B – $41.8B
|
$44.2B $42.1B – $45.1B
|
$46.6B $44.3B – $47.5B
|
| EBITDA |
$10.8B $10.1B – $11.1B
|
$11.3B $11.3B – $11.3B
|
$12.0B $11.4B – $12.2B
|
$12.6B $12.0B – $12.9B
|
| Net Income |
$8.3B $8.1B – $8.5B
|
$8.7B $8.1B – $9.3B
|
$9.8B $9.2B – $10.1B
|
$10.6B $9.9B – $10.9B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 23, 2026 3:02am (4d ago)| Metric | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Revenue Growth | -1.4% | +3.6% | +3.6% | +8.4% |
| Gross Profit Growth | -4.8% | +3.1% | +3.6% | +7.9% |
| Operating Income Growth | -4.6% | -6.2% | +15.8% | +8.6% |
| Net Income Growth | -25.4% | -2.2% | +26.8% | +3.0% |
| EBITDA Growth | -0.9% | -5.7% | +12.4% | +6.4% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-18 | Thompson Kweli | 0.00 | $0.00 | $0 | |
| 2026-06-18 | Thompson Kweli | 3,252.99 | $0.00 | $0 | |
| 2026-06-18 | Thompson Kweli | 9,178.81 | $0.00 | $0 | |
| 2017-08-01 | Thompson Kweli | 1,704.00 | $88.06 | $150,054 | |
| 2018-01-30 | Thompson Kweli | 1,608.00 | $74.67 | $120,069 | |
| 2018-07-31 | Thompson Kweli | 4,407.00 | $83.97 | $370,056 | |
| 2019-07-30 | Thompson Kweli | 6,271.00 | $89.08 | $558,621 | |
| 2020-07-29 | Thompson Kweli | 1,615.00 | $103.26 | $166,765 | |
| 2021-08-03 | Thompson Kweli | 10,181.00 | $97.33 | $990,917 | |
| 2022-08-02 | Thompson Kweli | 6,358.00 | $131.26 | $834,551 | |
| 2023-08-01 | Thompson Kweli | 26,890.00 | $93.08 | $2.5M | |
| 2024-07-31 | Thompson Kweli | 25,408.00 | $87.76 | $2.2M | |
| 2025-07-29 | Thompson Kweli | 1,540.00 | $80.00 | $123,200 | |
| 2026-07-28 | Thompson Kweli | 22,363.00 | $91.97 | $2.1M | |
| 2026-06-08 | KIIL HARRY SKIP | S-Sale | 3,961.00 | $80.44 | $318,623 |
| 2026-06-08 | KIIL HARRY SKIP | S-Sale | 228.00 | $80.45 | $18,343 |
| 2026-06-04 | KIIL HARRY SKIP | F-InKind | 6,817.00 | $83.32 | $567,992 |
| 2026-06-04 | Martha Geoffrey | F-InKind | 41,936.00 | $83.32 | $3.5M |
| 2026-06-04 | Marinaro Michael | F-InKind | 7,471.00 | $83.32 | $622,484 |
| 2026-06-04 | Walter Matthew R. | F-InKind | 2,840.00 | $83.32 | $236,629 |
Dividend History (Last 20)
Last updated: Jun 21, 2026 6:40pm (5d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-26 | $0.72 | 2026-06-03 | 2026-06-26 | 2026-07-17 |
| 2026-03-27 | $0.71 | 2026-03-05 | 2026-03-27 | 2026-04-17 |
| 2025-12-26 | $0.71 | 2025-12-04 | 2025-12-26 | 2026-01-16 |
| 2025-09-26 | $0.71 | 2025-08-14 | 2025-09-26 | 2025-10-17 |
| 2025-06-27 | $0.71 | 2025-05-20 | 2025-06-27 | 2025-07-11 |
| 2025-03-28 | $0.70 | 2025-03-06 | 2025-03-28 | 2025-04-11 |
| 2024-12-27 | $0.70 | 2024-12-05 | 2024-12-27 | 2025-01-10 |
| 2024-09-27 | $0.70 | 2024-08-15 | 2024-09-27 | 2024-10-11 |
| 2024-06-28 | $0.70 | 2024-05-22 | 2024-06-28 | 2024-07-12 |
| 2024-03-21 | $0.69 | 2024-03-07 | 2024-03-22 | 2024-04-12 |
| 2023-12-19 | $0.69 | 2023-12-07 | 2023-12-20 | 2024-01-12 |
| 2023-09-21 | $0.69 | 2023-08-17 | 2023-09-22 | 2023-10-13 |
| 2023-06-22 | $0.69 | 2023-05-24 | 2023-06-23 | 2023-07-14 |
| 2023-03-23 | $0.68 | 2023-03-02 | 2023-03-24 | 2023-04-14 |
| 2022-12-20 | $0.68 | 2022-12-08 | 2022-12-21 | 2023-01-13 |
| 2022-09-22 | $0.68 | 2022-08-18 | 2022-09-23 | 2022-10-14 |
| 2022-06-23 | $0.68 | 2022-05-25 | 2022-06-24 | 2022-07-15 |
| 2022-03-24 | $0.63 | 2022-03-03 | 2022-03-25 | 2022-04-22 |
| 2021-12-21 | $0.63 | 2021-12-09 | 2021-12-22 | 2022-01-14 |
| 2021-09-23 | $0.63 | 2021-08-20 | 2021-09-24 | 2021-10-15 |
Narrative Economics
market-narrative step).